The American Academy of Neurology (AAN) Annual Meeting brings together an international attendance of the neurology committee to promote the highest quality patient-centered neurologic care, convey the latest advances, and enhance career satisfaction.
Safety of Cancer Treatments in Patients With Multiple Sclerosis: Prashanth Rajarajan, MD, PhD
April 17th 2024The neurology resident at Massachusetts General Brigham talked about assessing the safety of cancer treatments in patients with multiple sclerosis using checkpoint inhibitors. [WATCH TIME: 6 minutes]
Pregnancy Outcomes of Maternal Exposure to Ocrelizumab: Riley Bove, MD
April 16th 2024The associate professor of neurology at University of California, San Francisco talked about findings from an analysis that assessed the safety of ocrelizumab when administered close to pregnancy. [WATCH TIME: 5 minutes]
Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD
April 15th 2024The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]
Cenobamate's Efficacy in Drug-Resistant Epilepsy: Jacob Pellinen, MD
April 14th 2024The assistant professor of neurology at University of Colorado School of Medicine discussed findings on the impact of cenobamate on hospital visits and emergency care for patients with drug-resistant epilepsy following surgery. [WATCH TIME: 3 minutes]
New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD
April 14th 2024The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]
Pridopidine Maintains Effectiveness in Huntington Disease Without Antidopaminergic Medications
April 14th 2024New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.
Pridopidine’s Impact on ALS, Assessing Results From HEALEY ALS Platform Trial: Melanie Leitner, PhD
May 23rd 2023The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]
Expanding Diversity in Neurology, Inclusive Communication and Accessibility: Diana M. Cejas, MD, MPH
May 19th 2023The assistant professor of neurology at the University of North Carolina at Chapel Hill discussed the importance of recognizing disability as part of diversity in neurology, emphasizing the need for inclusive communication and accessibility for disabled patients. [WATCH TIME: 10 minutes]
Potential for Preventing NMOSD, Improving Access to Panel Testing: Sean Pittock, MD
May 18th 2023The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided commentary on the possibility of preventing NMOSD, and the need to improve access to approved therapies and AQP4 testing. [WATCH TIME: 3 minutes]
Exploring the Risk of Hypertension Following Erenumab Treatment for Migraine: Nikita Chhabra, DO
May 17th 2023The neurology PGY-3 at Mayo Clinic in Arizona talked about findings from a retrospective cohort study that examined blood pressure in patients who were prescribed a migraine medication. [WATCH TIME: 6 minutes]